BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 17939047)

  • 21. The use of terlipressin in cirrhotic patients with refractory ascites and normal renal function: a multicentric study.
    Fimiani B; Guardia DD; Puoti C; D'Adamo G; Cioffi O; Pagano A; Tagliamonte MR; Izzi A
    Eur J Intern Med; 2011 Dec; 22(6):587-90. PubMed ID: 22075285
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High age and low sodium urine concentration are associated with poor survival in patients with hepatorenal syndrome.
    Hinz M; Wree A; Jochum C; Bechmann LP; Saner F; Gerbes AL; Gerken G; Canbay A
    Ann Hepatol; 2013; 12(1):92-9. PubMed ID: 23293199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Terlipressin Improves Renal Function and Reverses Hepatorenal Syndrome in Patients With Systemic Inflammatory Response Syndrome.
    Wong F; Pappas SC; Boyer TD; Sanyal AJ; Bajaj JS; Escalante S; Jamil K;
    Clin Gastroenterol Hepatol; 2017 Feb; 15(2):266-272.e1. PubMed ID: 27464593
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial.
    Solanki P; Chawla A; Garg R; Gupta R; Jain M; Sarin SK
    J Gastroenterol Hepatol; 2003 Feb; 18(2):152-6. PubMed ID: 12542598
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Poor outcomes with treatment of hepatorenal syndrome type 1 with splanchnic vasoconstrictors and albumin: report of seven cases and review of the literature.
    Kalil JR; Cerqueira LA; Barbosa DS; Motta MP; Nery Mda S; Bittencourt PL
    Arq Gastroenterol; 2009; 46(3):214-8. PubMed ID: 19918689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study.
    Moreau R; Durand F; Poynard T; Duhamel C; Cervoni JP; Ichaï P; Abergel A; Halimi C; Pauwels M; Bronowicki JP; Giostra E; Fleurot C; Gurnot D; Nouel O; Renard P; Rivoal M; Blanc P; Coumaros D; Ducloux S; Levy S; Pariente A; Perarnau JM; Roche J; Scribe-Outtas M; Valla D; Bernard B; Samuel D; Butel J; Hadengue A; Platek A; Lebrec D; Cadranel JF
    Gastroenterology; 2002 Apr; 122(4):923-30. PubMed ID: 11910344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Terlipressin therapy for renal failure in cirrhosis.
    Triantos CK; Samonakis D; Thalheimer U; Cholongitas E; Senzolo M; Marelli L; Leandro G; Patch D; Burroughs AK
    Eur J Gastroenterol Hepatol; 2010 Apr; 22(4):481-6. PubMed ID: 19952764
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Noradrenaline is as Effective as Terlipressin in Hepatorenal Syndrome Type 1: A Prospective, Randomized Trial.
    Goyal O; Sidhu SS; Sehgal N; Puri S
    J Assoc Physicians India; 2016 Sep; 64(9):30-35. PubMed ID: 27762512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Terlipressin in 30 patients with hepatorenal syndrome: results of a retrospective study.
    von Kalckreuth V; Glowa F; Geibler M; Lohse AW; Denzer UW
    Z Gastroenterol; 2009 Jan; 47(1):21-6. PubMed ID: 19156588
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.
    Cavallin M; Kamath PS; Merli M; Fasolato S; Toniutto P; Salerno F; Bernardi M; Romanelli RG; Colletta C; Salinas F; Di Giacomo A; Ridola L; Fornasiere E; Caraceni P; Morando F; Piano S; Gatta A; Angeli P;
    Hepatology; 2015 Aug; 62(2):567-74. PubMed ID: 25644760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome.
    Uriz J; Ginès P; Cárdenas A; Sort P; Jiménez W; Salmerón JM; Bataller R; Mas A; Navasa M; Arroyo V; Rodés J
    J Hepatol; 2000 Jul; 33(1):43-8. PubMed ID: 10905585
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome.
    Nazar A; Pereira GH; Guevara M; Martín-Llahi M; Pepin MN; Marinelli M; Solá E; Baccaro ME; Terra C; Arroyo V; Ginès P
    Hepatology; 2010 Jan; 51(1):219-26. PubMed ID: 19877168
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study.
    Ghosh S; Choudhary NS; Sharma AK; Singh B; Kumar P; Agarwal R; Sharma N; Bhalla A; Chawla YK; Singh V
    Liver Int; 2013 Sep; 33(8):1187-93. PubMed ID: 23601499
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Severe ischemic bowel necrosis caused by terlipressin during treatment of hepatorenal syndrome.
    Kim HR; Lee YS; Yim HJ; Lee HJ; Ryu JY; Lee HJ; Yoon EL; Lee SJ; Hyun JJ; Jung SW; Koo JS; Choung RS; Lee SW; Choi JH
    Clin Mol Hepatol; 2013 Dec; 19(4):417-20. PubMed ID: 24459647
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis.
    Rodríguez E; Elia C; Solà E; Barreto R; Graupera I; Andrealli A; Pereira G; Poca M; Sánchez J; Guevara M; Soriano G; Alessandria C; Fernández J; Arroyo V; Ginès P
    J Hepatol; 2014 May; 60(5):955-61. PubMed ID: 24447876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment-Related Cost Analysis of Terlipressin for Adults with Hepatorenal Syndrome with Rapid Reduction in Kidney Function.
    Huang X; Bindra J; Chopra I; Niewoehner J; Wan GJ
    Adv Ther; 2023 Dec; 40(12):5432-5446. PubMed ID: 37812332
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatorenal syndrome in patients with cirrhosis.
    Moreau R
    J Gastroenterol Hepatol; 2002 Jul; 17(7):739-47. PubMed ID: 12121502
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decreased need for RRT in liver transplant recipients after pretransplant treatment of hepatorenal syndrome-type 1 with terlipressin.
    Weinberg EM; Wong F; Vargas HE; Curry MP; Jamil K; Pappas SC; Sharma P; Reddy KR
    Liver Transpl; 2024 Apr; 30(4):347-355. PubMed ID: 37801553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting circulatory dysfunction in cirrhosis: terlipressin and the hepatorenal syndrome.
    Testro AG; Angus PW
    J Gastroenterol Hepatol; 2009 Nov; 24(11):1707-9. PubMed ID: 20136956
    [No Abstract]   [Full Text] [Related]  

  • 40. Terlipressin improves pulmonary pressures in cirrhotic patients with pulmonary hypertension and variceal bleeding or hepatorenal syndrome.
    Kalambokis GN; Pappas K; Tsianos EV
    Hepatobiliary Pancreat Dis Int; 2012 Aug; 11(4):434-7. PubMed ID: 22893473
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.